The formation of the inflammatory process in the prostatic tissue in most cases occurs with minimal clinical manifestations, and their clinical and diagnostic verification often does not reflect the actual state of the problem. This requires a search for clinical solutions in order to minimize the formation of inflammatory processes and the regulation of trophic functions in the compromised tissues of the prostate gland. The use of conservative therapy in people with chronic prostatitis and benign prostatic hyperplasia is considered the leading preventive and therapeutic method, therefore, the search for new and improvement of existing pharmacological drugs is an urgent issue.
The action of specific amino acid molecules of the mediator link of the bioregulation system – cytomedines, is due to the regulatory capabilities of low molecular weight peptides, which are multifunctional, capable of inducing the release of other regulatory substances and the formation of the so-called. «Peptide cascade» in a certain place in a short time. Their final effect is not enhanced by excessive intake, is not dose-dependent and is expressed by a complete systemic effect on general physiological processes (apoptosis, proliferation, various types of metabolism, regulation of genetic information).
Vitaprost is an extract of the prostate gland of bulls, lyophilized from an aqueous solution, among the organ peptides it stands out with high clinical efficacy and the absence of side reactions. Its main clinical effects are considered: anti-inflammatory (the ability to reduce edema and leukocyte infiltration in the tissues of the prostate gland), vascular (able to improve the processes of microcirculation and platelet-vascular homeostasis), trophic (a positive effect on spermatogenesis in the form of an increase in the functional activity of spermatozoa and the qualitative characteristics of sperm) , immunoregulatory (stimulates the activity of the humoral link of immunity and some factors of the body’s resistance), antimicrobial (stimulates the antimicrobial activity of neutrophils), neurotrophic (effect on the muscle tone of the urinary bladder and rectum).
The use of prostatilen, as an organotropic polypeptide with high tissue specificity, is a justified pharmacological model for the treatment of infectious-inflammatory and congestive conditions in the structures of the prostate-vesicular complex in men of various ages. The positive effect of prostatilen is due to a series of complementary pathogenetic mechanisms, which include anti-inflammatory, immunotropic, trophic and neurovascular effects on the above structures.
The clinical effect of the rectal form of prostatilen, demonstrated in cases of a combination of chronic prostatitis with benign prostatic hyperplasia and confirmed by a series of long-term studies, makes it possible to use it both in mono- and in combination therapy of these conditions, taking into account the individual conditions of the course of the disease.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
Alyaev YG, Apolikhin OI, Mazo EB et al. Results of a three-year clinical study to study the efficacy and safety of Prostamol® Uno in patients with initial manifestations of prostate adenoma and the risk of progression. Urology. 2010;6:3–10.
Mazo EB, Dmitriev DG, Zikanov VV. Combined treatment of patients with benign prostatic hyperplasia in combination with chronic prostatitis with suspected prostate cancer // BC. 2005;13(9):615–8.
Gorpinchenko II, Gurzhenko YN, Spiridonenko VV. Theoretical reconsideration and practical possibilities of effective treatment of rectal forms in case of chronic prostatitis. Medic. aspects of male health. 2015;19:30–42.
Efremov E, Kasatonova E, Melnik Y, Nikushina A. Influence of COVID-19 on male fertility. What is already known? Urologiia. 2020;(4):104–10.
Nickel JC. Prostatic inflammation in BPH: the third component? Can J Urol. 1994;1 Р:1–4.
Di Silverio F, Gentile V, De Matteis A. et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003; 43:164–175.
De Marzo AM, Platz EA, Sutcliffe S. et al. Inflammation in prostate carcinogenesis. Nat Rev. 2007;7: 256–69.
De Marzo AM, Marchi VL, Epstein JI, Nelson WG. (1999) Proliferative inflammatory atrophy of the prostate. Am.J.Pathol. 1999;155:1985–92.10.1016/S0002-9440(10)65517-4
Nelson WG, De Marzo AM, Isaacs WB. (2003) Prostate cancer // N. Engl. J. Med. V.349. P. 366–381.
Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51:1202–16.
Djavan B. Lower urinary tract symptoms benign prostatic hyperplasia: fast control of the patient’s quality of life. Urology. 2003;62:6–14.
Dennis L, Lynch CF, Tornes JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60:78–83.
Karakiewicz PI, Benayoun S, Begin LR. et al. Chronic inflammation is negatively associated with prostate cancer and high grade prostatic intraepithelial neoplasia on needle biopsy. Int J Clin Pract. 2007;71:425–30.
Morozov VG, Khavinson V.Kh. A new class of biological regulators of multicellular systems – cytomedins. Advances in modern biology. 1983;96(3):339–352.
Khavinson V, Kuznik B, Ryzhak G. Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol. 2013;26(1):20–37. 24003726
Lezhava T, Monaselidze J, Kadotani T, Dvalishvili N, Buadze T. Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Med News. 2006;133:111–5.
Ryzhak A, Chalisova N, Lin’kova N, Khalimov R, Ryzhak G, Zhekalov A. Polypeptides influence on tissue cell cultures regeneration of various age rats. Adv Gerontol.2015;28(1):97–103.
Kuzmin IV, Borovets SYu, Gorbachev AG, Al-Shukri SKh. Prostatic bioregulatory polypeptide prostatilen: pharmacological properties and experience of 30 years of clinical use in urology. Urol.statements. 2020;3(10):243–258.
Fedoreeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescently labeled peptides into the nucleus in HeLa cells and the specific interaction of peptides with deoxyribooligonucleotides and DNA in vitro. Biochemistry. 2011;11(76):1505–16.
Khavinson VKh, Anisimov VN. 35 years of experience in the study of peptide regulation of aging // Advances in gerontology. 2009;22(1):11–23.
Petrishchev NN, Mikhailova NA, Gorbachev AG et al. Effect of a complex of polypeptides isolated from the prostate gland of animals on thrombus formation. Patol. physiology and expert. therapy. 1991;4(35):5–6.
Al-Shukri SKh, Gorbachev AG, Kuzmin IV, Khavinson VKh. () Introduction to bioregulatory therapy for urological diseases. SPb. Nauka. 1996:93.
Barabanova VV, Gorbachev AG, Parastaeva MM, Khavinson VKh. Influence of peptides of the prostate gland on the contractile activity of smooth muscle cells of the urinary bladder. Fiziol. zhurn. them. THEM. Sechenov. 1993;79 (2):906.
Al’-Shukri S, Aĭvazian A, Barabanov S. et al. Influence of prostatilen on smooth muscle organs functional activity in surgical patients (clinical and experimental study). Khirurgiia (Mosk).1999;(1):47–9.
Yushkov VV, Khavinson VKh. (1993) Identification and analysis of anti-inflammatory activity of immunomodulators. Pathologist. fiziol. and expert. therapy. 1993;37;2:11–3.
Gorbachev AG, Napalkov PN, Totolyan AA, Khavinson VKh. The effect of a polypeptide preparation from the prostate gland (prostatilen) on the parameters of the immune status of patients with chronic prostatitis / Sat. theses of the IV All-Union. congress of urologists. Moscow, October 10-12. 1990:261–2.
Al-Shukri SKh, Gorbachev AG, Kuzmin IV. Influence of prostatilen on the metabolic activity of phagocytes in patients with chronic pyelonephritis. Kazan. medits. zhurn. 1996.3(77):200–1.
Al-Shukri SKh, Gorbachev AG, Kuzmin IV. Bioregulatory therapy of patients with chronic pyelonephritis. Urol. and nephrole.1997;4:6–8.
Mukaida N. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 1998;9(1):9–23.
Klyasheva RI, Sergeeva VE, Klochkova EA. The effect of prostatilen on the content of triglycerides in the blood serum and catecholamines in the testes of rats “Aktual. directions of scientific. issled. XXI century: theory and practice”. 2013;3:45–50.
Klyasheva RI, Sergeeva VE, Klochkova EA. Study of the effect of prostatilen on total serum cholesterol and serotonin levels in mentees. Vestn. Chuvash University. 2014;2:266–9.
Klyasheva RI, Sergeeva VE, Klochkova EA. Study of the effect of prostatilen on serum uric acid and histamine levels in rat testes. Acta Medica Eurasica. 2015;1:1–5.
Khavinson VKh, Morozov VG, Kuznik BI et al. Influence of prostate polypeptides on the hemostatic system // Pharmacology and toxicology. 1985;48;5:69–71.
Al-Shukri SKh, Petrishchev NN, Gorbachev AG. Influence of prostatilen on indicators of hemostasis in chronic prostatitis (clinical and experimental study). Urol. and nephrole. 1997;3:38–41.
Kuzmin IV. (Prostatilen in the treatment of chronic pyelonephritis (experimental clinical study): Author’s abstract. dis. ... Cand. honey. sciences. – SPb., 1996. 24 p.
Tsukanov AYu, Lyashev RV. Disruption of venous blood flow as a cause of chronic abacterial prostatitis (chronic pelvic pain syndrome). Urology. 2014;4:33–8.
Savateeva-Liubimova T, Sivak K, Malinin V. Effect of prostatilen AC suppositories on course of experimental prostatitis. Urologiia. 2012;4:50–2.
Al’-Shukri S, Bobkov I, Gorbachev A, Kuz’min I, Tkachuk V. Our experience in the use of prostatilen in urology. Urologiia. 2003;6:32–6.
Novikov V, Al’-Shukri S, Gorbachev A, Tiurin A, Amdiĭ R, Iastrebov D. Prophylactic use of prostatilen in rats prior to exposure to + Gz loads as a way of reducing changes in urogenital organs Aviakosm Ekolog Med;1997;31(2):25–7.
Al-Shukri SKh, Petrishchev N, Gorbachev A et al. The effect of prostatilen on the hemostatic indices in chronic prostatitis (a clinical and experimental study) Urol Nefrol (Mosk). 1997;3:38–41.
Al-Shukri SKh, Gorbachev AG, Borovets SY, Tyurin AG, Knyazkin IV. On the pathogenesis and prevention of chronic prostatitis (clinical experimental study). Urol. Statements. 2012;2(2):15–19.
Vozianov AF, Gorpinchenko II, Boyko NI et al. The use of prostatilen in the treatment of patients with prostate diseases. Urology and Nephrology. 1991;6:43–46.
Gorbachev AG, Borovets SYu, Al-Shukri SKh, Rybalov MA. The effectiveness of combined bioregulatory therapy (prostatilen and thymogen) in patients with infectious chronic prostatitis. Nephrology. 2015;19;6:49–52.
Selkov SA, Petlenko SV, Selkova MS. The use of the drug prostatilen in the complex therapy of chronic prostatitis associated with sexual and reproductive disorders. Andrology and genital surgery. 2012;13;3:93–6.
Al-Shukri SKh, Petlenko SV, Borovets SYu. et al. The effect of Prostatilen® AC and Prostatilen® on the level of antisperm antibodies in the ejaculate in the treatment of patients with chronic abacterial prostatitis and concomitant reproductive disorders. Andrology and Genital Surgery. 2016;17;1:38–41.
Zhukov OB, Bragina EE, Levina AV et al. Comparison of the effectiveness of drugs containing a combination of arginine and zinc in the treatment of male infertility. Andrology and genital surgery. 2020;21;2;26–35.
Borovets SYu., Rybalov MA, Gorbachev AG, Al-Shukri SKh. The effect of Prostatilen® AC on sperm DNA fragmentation in the treatment of patients with chronic abacterial prostatitis and concomitant reproductive disorders. Andrology and Genital Surgery. 2017;18;3:54–58.
Borovets SYu., Rybalov MA, Gorbachev AG et al. Long-term results of treatment with Prostatilen® AC in patients with chronic abacterial prostatitis with an increased degree of sperm DNA fragmentation. Andrology and Genital Surgery. 2018;19;2:52–7.
Al-Shukri SKh, Gorbachev AG, Borovets SYu. et al. Treatment of patients with prostate adenoma with prostate lesions. Urology. 2006;6:22–5.
Al-Shukri SK., Gorbachev AG, Borovets SYu. et al. The effect of prostatilen on urinary disorders in patients with benign prostatic hyperplasia. Urology. 2005;5:25–26.
Borovets SYu, Gorbachev AG, Al-Shukri SKh, Rybalov MA. On the pathogenetic substantiation of the course treatment with peptide bioregulators in patients with benign prostatic hyperplasia. Nephrology. 2015;19; 4:108–11.
Al’-Shukri SK, Gorbachev A, Borovets S, Belousov V, Kuz’min I, Chushkin K. Prostatilen treatment of prostatic adenoma. Urologiia. 2006;6;22:25–6.
Iaitskiĭ N, Aĭvazian I, Al-Shukhri S, Gorbachev A. The treatment of acute reflex urinary retention after operations in the area of the rectal sphincter. Vestn Khir Im I I Grek. 1996;155(6):80–1.
Uchvatkin GV, Tatarintseva MB. Prostatic peptides in the treatment of prostate diseases. Urologist. messenger. 2017;3(7):44–8.
Gomberg V, Nad ‘I. Efficacy of Vitaprost Forte in the treatment of adenoma. Urologiia. 2010;5:35–9.
Korneev I. Russian experience with Vitaprost Forte suppositories in patients with lower urinary tract symptoms and benign prostatic hyperplasia: comparative analysis of studies. Urologiia. 2017;3:138–44.
Shafranov D, Mariupol’skiĭ A. Vitaprost-forte in the treatment of patients with prostatic adenoma Urologiia. 2011;6(54):56–9.
Fujita K, Ewing CM, Getzenberg RH, et al. Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate. 2010;70(5):473–81.
Belostotskaya LI, Nikitchenko YuV, Gomon ON et al. The effect of biologically active substances of animal and plant origin on the prooxidant-antioxidant balance in experimental prostatic hyperplasia in rats. Expert. and a wedge. pharmacol. 2006;69;4:66–8.
Soroka I.V., Petlenko S.V. (2012) Clinical and laboratory efficacy of monotherapy with Prostatilenum for benign prostatic hyperplasia with lower urinary tract syndrome. Honey. news. No. 5. P. 59–61.
Al-Shukri SKh, Tkachuk VN, Gorbachev AG, et al. Urodynamic studies in the diagnosis of bladder outlet obstruction in men. Urol. and nephrol. 1998;6:27–9.
Al-Shukri SKh, Amdiy RE, Kuzmin IV. Decreased bladder contractility in patients with benign prostatic hyperplasia. Urol. 2011;1:3–8.
Akomolafe Seun F, Olasehinde T, Aluko BT. Diets supplemented with raw and roasted pumpkin (Cucurbita pepo L) seeds improved some biochemical parameters associated with erectile function in rats. J Food Biochem. 2021;45;2.
Oyetayo FL, Akomolafe SF, Osesanmi TJ. Effect of dietary inclusion of pumpkin (Cucurbita pepo L) seed on nephrotoxicity occasioned by cisplatin in experimental rats. J Food Biochem. 2020;18:134–39.
Tantawy SA, Elgohary HM, Kamel DM. Trans-perineal pumpkin seed oil phonophoresis as an adjunctive treatment for chronic nonbacterial prostatitis. Res Rep Urol. 2018;18;10:95–101.
Procida G, Stancher B, Cateni F, Zacchigna M. Chemical composition and functional characterization of commercial pumpkin seed oil. J Sci Food Agric. 2013;93(5):1035–41.